Cirrhosis, Liver Clinical Trials

17 studies are recruiting for cirrhosis, liver in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

   Loss of skeletal muscle mass or sarcopenia is the most common and potentially reversible complication in cirrhosis that increases morbidity and mortality before, during and after liver transplantation. No proven treatments exist for the prevention or reversal of sarcopenia in cirrhosis, primarily b…

   Stage

   Not phased

   Ages

   18 to 70

   Site

   Cleveland Clinic Foundation, Cleveland, Ohio

   Run by

   The Cleveland Clinic

   See if you can join NCT03208868 on ClinicalTrials.gov

2. Measuring Patient Reported Needs in Outpatient Liver Disease Management

   This prospective study aims to assess health-related social needs (HRSNs) among patients with chronic liver disease (CLD) receiving outpatient care at Indiana University Health. Patients with CLD often face socioeconomic challenges that adversely affect health outcomes, but no validated screening t…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Indiana University School of Medicine, Indianapolis, Indiana

   Run by

   Indiana University

   See if you can join NCT07191886 on ClinicalTrials.gov

3. Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

   This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   University of California San Diego NAFLD Research Center, La Jolla, California

   Locations

   13 in total

   Run by

   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

   See if you can join NCT05832229 on ClinicalTrials.gov

4. Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant

   The goal of this observational study is to establish risk factors for post-transplant in adult individuals with cirrhosis without diabetes undergoing liver transplant evaluation. The question being addressed is: can laboratory work, anthropometric tests, functional tests, imaging, and advanced meas…

   Stage

   Not phased

   Ages

   18 to 75

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT06950788 on ClinicalTrials.gov

5. Initial Resuscitation for Acute Kidney Injury in Cirrhosis

   The goal of this interventional study is to evaluate two strategies for how to provide intravenous (IV) fluids for treating patients with acute kidney injury (AKI) in cirrhosis. The main question it aims to answer is: what is the safety, efficacy, and feasibility of providing a recommendation to us…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT06525623 on ClinicalTrials.gov

6. Transitional Care Program for Fluid Overload in Cirrhosis

   The goal of this clinical trial is to learn about an intensive monitoring plan (transitional care program) in patients with cirrhosis and excessive swelling that are going to be discharged from the hospital. The main question[s] it aims to answer are: * How much time and what resources are needed t…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania

   Run by

   Milton S. Hershey Medical Center

   See if you can join NCT06174272 on ClinicalTrials.gov

7. Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

   This is a single-arm, phase II study of patients with advanced liver cancer or hepatocellular carcinoma (HCC) who are eligible for first-line treatment with T300+D. The invesitgators hypothesize that T300+D will be safe and tolerated in CP-B patients with HCC. HCC mostly affects disadvantaged popul…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UT Health San Antonio, San Antonio, Texas

   Run by

   The University of Texas Health Science Center at San Antonio

   See if you can join NCT06526104 on ClinicalTrials.gov

8. HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis

   Loss of skeletal muscle mass or sarcopenia is the most common and potentially reversible complication in cirrhosis that increases morbidity and mortality before, during and after liver transplantation. No proven treatments exist for the prevention or reversal of sarcopenia in cirrhosis, primarily b…

   Stage

   Not phased

   Ages

   21 to 65

   Site

   Cleveland Clinic, Cleveland, Ohio

   Run by

   The Cleveland Clinic

   See if you can join NCT05166499 on ClinicalTrials.gov

9. Molecular Mechanism of Exercise in Cirrhosis

   This study aims to investigate the effects of 12 weeks of resistance or endurance exercise on patients with cirrhosis. Cirrhotic patients are prone to muscle loss (sarcopenia) and ammonia build up due to liver dysfunction. The liver which in healthy patients is able to process ammonia through ureag…

   Stage

   Not phased

   Ages

   21 to 65

   Site

   Cleveland Clinic, Cleveland, Ohio

   Run by

   The Cleveland Clinic

   See if you can join NCT05982769 on ClinicalTrials.gov

10. A Study of SIPLIZUMAB in AILD and LT Patients

    There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York

    Run by

    Elizabeth C. Verna

    See if you can join NCT06455280 on ClinicalTrials.gov

11. The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial

    The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) trial is a single center prospective adaptive phase 1b clinical trial in patients who are hospitalized with complications of liver disease and have low fecal metabolite levels (butyrate and deoxycholic acid). The study intervent…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Chicago Medical Center, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT06871111 on ClinicalTrials.gov

12. Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

    This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the m…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Arizona Liver Health, Chandler, Arizona

    Locations

    9 in total

    Run by

    PharmaIN

    See if you can join NCT05490888 on ClinicalTrials.gov

13. EGCG for Hepatocellular Carcinoma Chemoprevention

    This phase II trial tests epigallocatechin gallate (EGCG) for its efficacy and safety in preventing development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UT Southwestern, Dallas, Texas

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT06015022 on ClinicalTrials.gov

14. Evaluation of Non-Invasive Tests for Metabolic Liver Disease

    The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis …

    Stage

    Not phased

    Ages

    18 to 75

    Site

    Clinical Pharmacology of Miami, Miami, Florida

    Locations

    4 in total

    Run by

    Foundation for the National Institutes of Health

    See if you can join NCT07122700 on ClinicalTrials.gov

15. LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease

    The goal of this clinical trial is to evaluate whether early integration of palliative care in the care of hospitalized patients with advanced liver disease (AdvLD) can improve patients' quality of life, physical symptoms, mood, and serious illness communication. Palliative care is a medical specia…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05998330 on ClinicalTrials.gov

16. Danazol for Treatment of Cytopenias in Patients With Cirrhosis

    This is a phase II pilot study designed to assess the safety and efficacy of danazol for treatment of cytopenias in patients with CPC A/B cirrhosis. Subjects with or without telomere mutations and/or shortened telomeres will be treated with danazol 600 mg per day by mouth for a duration of 24 month…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Keck Hosital of USC, Los Angeles, California

    Run by

    University of Southern California

    See if you can join NCT04873102 on ClinicalTrials.gov

17. Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

    Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Mercy Medical Center, Baltimore, Maryland

    Run by

    Mercy Medical Center

    See if you can join NCT04588077 on ClinicalTrials.gov